Services
A therapy proven in the lab is not yet a therapy a patient can receive. Someone still has to deliver it — and build the device that carries it.
ECCT works because a field can find a dividing cell from outside the body. But knowing that doesn't get a garment onto a patient, doesn't monitor whether the therapy is doing anything once it's there, and doesn't build the thousandth electrode unit to the same standard as the first prototype. Between the physics and the person are two ordinary, unglamorous problems: delivering the therapy safely, and manufacturing the device that delivers it.
CTECH Labs runs both in-house rather than handing them to a distant partner. A dedicated facility administers ECCT under physician oversight and tracks its effect through the same ECVT imaging that made the therapy possible in the first place. A separate manufacturing line builds every electrode garment and stimulation unit the company ships, audited against the same quality standard hospitals expect. Neither is the science — both are what make the science reach anyone at all.
ECCT's field has to be fitted to an actual tumour in an actual body, at the right frequency and intensity for that cancer type, worn for the right number of minutes a day, for weeks. Getting that right — and knowing whether it's working — is a clinical job, not an engineering one, and it's what the Cancer Therapy Lab exists to do: patient assessment, a body-conforming electrode garment fitted to the tumour site, active therapy delivered mostly at home, and periodic ECVT imaging that reads the tumour's changing permittivity the same way the original scanner read a fluidised bed.
Since ethical clearance in 2012, that pathway has run for a reported more than 5,000 patients across glioblastoma, breast, lung, liver, and cervical cancers — including the roughly 37% of cases who combine ECCT with ongoing chemotherapy or radiotherapy rather than replacing it, and the patients who arrive after other options have run out. The lab is also where the clinical evidence keeps accumulating: a case series presented at GLOBEHEAL 2026 reported substantially longer survival in advanced lung cancer patients using ECCT alongside standard therapy, and ECVT monitoring has been validated against MRI and PET-CT as a radiation-free way to watch a tumour respond. These findings come from case series and conference presentations rather than independent, large-scale randomized trials, and Indonesian health authorities have said ECCT's efficacy requires further evidence.
Explore the Cancer Therapy Lab →A prototype that works on a bench doesn't automatically work on a thousand different bodies, worn eight hours a day, day after day. Getting from one to the other is Wearables Manufacture's job: engineering and revising the garment electronics for each device — the ECCT helmet, blanket, and pants forms, and the ECBS stimulation units — sourcing and verifying the components that go into them, assembling each unit in-house, and testing it for function and safety before it ships to the Cancer Therapy Lab, a clinical partner, or a patient directly.
None of that is invisible to regulators. In January 2026, Revotera Medical Technologies ran a combined ISO 13485 quality management system audit and critical supplier audit across CTECH's ECCT and ECVT manufacturing lines at once — part of aligning production quality with what the global market, not just a single clinic, expects from a medical wearable.
Explore Wearables Manufacture →